Steve R. Bailey
@Frazier Life Sciences Management, L.p.
Latest period2024 - Q3ReportedManaged Assets$2.495BTotal holdings53
Assets growth rate16.72%Assets growth rate (2-Q avg)3.46%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Frazier Life Sciences Management, L.p.'s 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 53 positions.
Assets under management
The assets under management (AUM) of Frazier Life Sciences Management, L.p. over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 2.495B in assets, with a quarterly growth rate of 16.72% and a 2-quarter average growth rate of 3.46%. The portfolio is managed by Steve R. Bailey, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
MBXMbx Biosciences Inc
| 6.24% | $155.499M 5.985M shares@ $25.98 avg price | New Position |
ASNDAscendis Pharma A S
| 0.8% | $19.908M 133,333 shares@ $149.31 avg price | New Position |
ALKSAlkermes Plc
| 0.65% | $16.126M 576,129 shares@ $28.0 avg price | New Position |
ORKAOruka Therapeutics Inc
| 0.47% | $11.699M 477,327 shares@ $24.52 avg price | New Position |
LXEOLexeo Therapeutics Inc
| 0.46% | $11.307M 1.251M shares@ $9.04 avg price | New Position |
DAWNDay One Biopharmaceuticals I
| 0.39% | $9.607M 689,655 shares@ $13.93 avg price | New Position |
NUVBNuvation Bio Inc
| 0.12% | $2.79M 1.218M shares@ $2.29 avg price | New Position |
PIRSPieris Pharmaceuticals Inc
| 0.02% | $266,869 15,942 shares@ $16.74 avg price | New Position |